Precise engineering of nanoassembled Corilagin small molecule into supramolecular nanoparticles for the treatment and care against cervical carcinoma

Cervical cancer is one of the most frequently diagnosed tumors in the world and responsible for a significant percentage of women's deaths. In spite of advances in clinical and medical techniques, cervical cancer is indeed a big challenge. Latest treatments to breast cancer include surgical reduction, radiotherapy, estrogen treatment and the use of multiple chemotherapeutic medications. However, drug resistance, related severe adverse reactions, metastases and recurrence risks do need to be tackled, involving safe and alternate methods. Herein, we present tumor-specific targeting supramolecular nanoassembly, and therapeutically to overcome the different challenges raised by the distribution of the pharmaceutical potential anticancer drug Corilagin. On covalent conjugations of hydrophobic linoleic acid by carboxylic group, the Corilagin prodrugs were skilled in impulsively nanoassembly into extremely stable nanoparticles size (similar to 100 nm). Electron microscopic techniques have examined the newly synthesized morphology of Corilagin-NPs. The anticancer properties of Corilagin and Corilagin-NPs against CaSki and HeLa (cervical carcinoma) cancer cell lines have been evaluated after successful synthesis. Other research, such as dual staining acridine orange/ethidium bromide, Hoechst 33344 and flow cytometry study on the apoptosis mechanisms, have shown that proliferation in cervical cancer cells is associated with apoptosis. Compared to Corilagin, Corilagin-NPs demonstrate excellent biocompatibility, this study clarified the Corilagin-NPs as a healthy and cervical cancer care chemotherapeutics technique and deserve further clinical evaluations.